8-K 1 a2082007z8-k.txt 8-K ================================================================================ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ------------------ FORM 8-K CURRENT REPORT FILED PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): JUNE 7, 2002 ENCHIRA BIOTECHNOLOGY CORPORATION (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE 0-21130 04-3078857 (STATE OR OTHER JURISDICTION OF (COMMISSION FILE NUMBER) (I.R.S. EMPLOYER INCORPORATION OR ORGANIZATION) IDENTIFICATION NO.) 4200 RESEARCH FOREST DRIVE THE WOODLANDS, TEXAS 77381 (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES AND ZIP CODE) (281) 419-7000 (REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE) --------------- ================================================================================ ITEM 5. OTHER EVENTS On June 7, 2002, Enchira Biotechnology Corporation (the "Company") issued a press release announcing that the Nasdaq Stock Market has approved the company's request to transfer its common stock to the Nasdaq SmallCap Market from the Nasdaq National Market effective opening of business, June 7, 2002. The stock will continue trading under the symbol ENBC. The company requested the transfer to the Nasdaq SmallCap Market because it was unable to meet the $1.00 per share closing bid requirement of the Nasdaq National Market for the minimum number of consecutive trading days. The Nasdaq SmallCap Market has the same $1.00 closing bid requirement, but the company has until at least August 13, 2002 to demonstrate compliance with such requirement under Nasdaq SmallCap Market rules for a period of at least ten consecutive trading days. If the company fails to demonstrate compliance by August 13, 2002, the company may be eligible for a grace period of 180 days after such date to demonstrate compliance with the $1.00 closing bid requirement if the company is in compliance with the Nasdaq SmallCap Market core listing standards. The press release is filed as an exhibit to this Current Report on Form 8-K and is incorporated by reference herein. ITEM 7. EXHIBITS Exhibit 99.1 -- Press Release SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENCHIRA BIOTECHNOLOGY CORPORATION Date: June 7, 2002. By: /s/ PAUL G. BROWN, III --------------------------------------------- Paul G. Brown, III President, Chief Financial Officer and Vice President, Finance and Administration